The QualityStocks Daily Monday, June 3rd, 2019

Today's Top 3 Investment Newsletters

CannabisNewsWire (GRYN) +32.65%

SmallCapRelations (ENDV) +28.73%

QualityStocks (ALYE) +25.91%

The QualityStocks Daily Stock List

GrowGeneration Corp. (GRWG)

NetworkNewsWire, Zacks, Wall Street Alerts, CannabisMarketCap, Micro Small Cap, Marketbeat, Pot Stock News, Insider Financial, New Cannabis Ventures, Stockwatch, TipRanks and Stockhouse reported on GrowGeneration Corp. (GRWG), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

GrowGeneration Corp. is the largest chain of specialty retail hydroponic and organic garden centers, with 24 locations serving commercial and home growers. In addition, the Company operates an online superstore for cultivators, at GrowGeneration’s mission is to own and operate GrowGen branded stores in all the major legalized cannabis States in the U.S. and Canada. OTCQX-listed, GrowGeneration is based in Denver, Colorado.

GrowGen has 5 locations in Colorado, 6 locations in California, 2 locations in Las Vegas, 1 location in Washington, 3 locations in Michigan, 1 location in Rhode Island, 2 locations in Oklahoma, 3 locations in Maine, and 1 location in New Hampshire. The Company carries and sells thousands of products. These include organic nutrients and soils, advanced lighting technology and state of the art hydroponic equipment to be used indoors and outdoors by commercial and home growers.

In May, GrowGeneration announced that it purchased the assets of GreenLife Garden Supply, with 2 locations in Maine and 1 location in New Hampshire. Following the acquisition, GrowGeneration now has 5 retail and warehouse locations serving the growing number of commercial cultivators in the New England market.

GrowGenerations CEO, Mr. Darren Lampert, said, "GreenLife marks our 5th acquisition in 2019, adding $7 Million in revenue to our Company. GreenLife, strategically located in the heart of New England, adds one of the largest and highest volume hydroponic chains in the country. Further, this acquisition positions the Company well to service the adjacent states, New York and New Jersey, that have been actively moving towards adult-use legalization. GreenLife has a seasoned team and we are excited that the founder, Sean Reardon will be continuing in an executive sales and business development role for GrowGen."

For Q1 2019, GrowGeneration had Net income of $229,421 versus a Net Loss of $(953,430) for Q1 2018. Revenue was $13.1 million up $8.7 million or 199 percent over Q1 2018 Revenue of $4.4 million. Same Store Sales were up 42 percent for Q1 2019 versus Q1 2018. Gross Profit Margin percentage was 28.2 percent for Q1 2019 versus 27.1 percent for Q1 2018.

GrowGeneration Corp. (GRWG), closed Monday's trading session at $3.03, down 0.98%, on 155,673 volume with 199 trades. The average volume for the last 3 months is 130,880 and the stock's 52-week low/high is $2.05/$5.10.

Enterprise Diversified, Inc. (SYTE)

OTC Dynamics, Stockhouse, AI Stock Finder, PR Newswire, Stockopedia, Whale Wisdom and Marketbeat reported earlier on Enterprise Diversified, Inc. (SYTE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Enterprise Diversified, Inc. is mainly an alternative asset manager with interests in several diverse business activities in the asset management, real estate, and internet access industries. Its companies include Willow Oak Asset Management, Mt Melrose, and The Company was previously known as Sitestar Corporation. It changed its name to Enterprise Diversified, Inc. in July of 2018. Enterprise Diversified has its corporate office in Richmond, Virginia.

Willow Oak Asset Management holds interests in private investment partnerships. By way of its Fund Management Services, Willow Oak provides operational, marketing, as well as investor relations support to niche fund managers. Willow Oak Asset Management produced $696,980 in revenue for the quarter ending March 31, 2019. The chief driver of the quarter's gain is the result of a direct investment in Alluvial Fund.

Mt Melrose is a Lexington, Kentucky based real estate holding company. It has a large portfolio of residential and commercial properties. Mt Melrose continues to seek out undervalued properties, rehabilitate and rent them, and own them indefinitely.

Furthermore, Enterprise Diversified directly owns a real estate investment portfolio. This portfolio includes residential properties, vacant land, and one commercial property. This portfolio is mainly focused in the Roanoke and Lynchburg areas of Virginia.

Enterprise Diversified's Internet Operations are managed under offers consumer and business-grade internet access, wholesale managed modem services, web hosting, and different ancillary services to customers in the U.S. and Canada.

Last week, Enterprise Diversified announced that it sold its Phoenix-based home services subsidiary, Specialty Contracting Group, LLC (formerly known as HVAC Value Fund, LLC). Enterprise Diversified provided certain assets to the buyer in exchange for a royalty stream over the next five years. Enterprise Diversified will receive 7.5 percent of revenue generated from qualified sales in the first year and 5 percent of revenue in years two through five. Other nonmaterial assets and liabilities were assumed by the buyer.

Enterprise Diversified, Inc. (SYTE), closed Monday's trading session at $5.55, up 0.91%, on 8,124 volume with 12 trades. The average volume for the last 3 months is 2,727 and the stock's 52-week low/high is $5.09/$18.00.

Repro Med Systems, Inc. (REPR)

Marketbeat, Zacks, Streetwise Reports, Market Screener, Wallmine, InvestorsHub, Wallet Investor, Simply Wall St, Infront Analytics, Business Wire, Equity Clock, Dividend Investor, Stockwatch, Capital Cube, and Stockhouse reported previously on Repro Med Systems, Inc. (REPR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Repro Med Systems, Inc. does business as RMS Medical Products (REPR) (RMS Medical). RMS Medical develops, manufactures and commercializes innovative and user-friendly specialty infusion solutions that improve quality of life for patients worldwide. The Company has its FREEDOM Syringe Infusion System. OTCQX-listed, Repro Med Systems has its head office in Chester, New York.

The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. The Company sells its products through direct sales and medical device distributors, as well as online.

Repro Med Systems announced this past April that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its HIgh-Flo Super26™ Subcutaneous Needle Sets (Super 26 Needle Sets). The Super26 Needle Sets are indicated for subcutaneous infusion of medications in the home, hospital, or ambulatory settings to facilitate high flow rates. This includes human plasma-derived immunoglobulins such as Hizentra® and Cuvitru™. Expanding on RMS Medical’s well-regarded lineup of HIgH-Flo needle sets, the Super26 Needle Sets use a proprietary design to provide 26-gauge comfort with significantly faster flow rates.

In May, Repro Med Systems (dba RMS Medical Products) announced that Mr. R. John Fletcher was appointed as an independent member of RMS Medical’s Board of Directors. With this appointment, RMS Medical’s Board of Directors fills the vacancy created by the passing of Mr. Arthur J. Radin. Mr. Fletcher brings greater than 35 years of healthcare and medical device experience to RMS Medical. Currently, he serves as Chief Executive Officer and Managing Director of Fletcher Spaght, Inc., which is a strategy consulting and venture capital firm that he founded in 1983.

RMS Medical’s Chairman, Mr. Dan Goldberger, is scheduled to present at the 9th Annual LD Micro Invitational on June 5, 2019. The event is being held at the Luxe Sunset Hotel in Bel-Air, California. RMS Medical’s presentation will take place at 10:20 am Pacific Time.

Repro Med Systems, Inc. (REPR), closed Monday's trading session at $1.70, down 3.41%, on 17,400 volume with 13 trades. The average volume for the last 3 months is 20,668 and the stock's 52-week low/high is $1.115/$1.79.

Gran Colombia Gold Corp. (TPRFF)

Micro Small Cap, Mining & Energy, Junior Mining Network, Metals News, GuruFocus, Gold Stock Data, Wallet Investor, The Prospector News, and Resource World reported earlier on Gran Colombia Gold Corp. (TPRFF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Gran Colombia Gold Corp. is a mid-tier gold producer. The Company’s main focus is in Colombia where it is currently the largest underground gold and silver producer with several mines in operation at its Segovia and Marmato Operations. Gran Colombia is presently in the midst of an expansion and modernization project at its high grade, production stage Segovia Operations. Gran Colombia Gold lists on the OTC Markets’ OTCQX. The Company is based in Toronto, Ontario.

Gran Colombia’s emphasis is on the development of the Segovia Operations and Marmato projects to generate strong cash flows in the short, medium and long term. The Company produces gold from the Segovia Operations, an area of approximately 9,000 hectares in the Segovia-Remedios mining district of Antioquia. The Segovia Operations include the El Silencio, Providencia and Sandra K underground mines in the Municipality of Segovia, and the Carla underground mine in the Municipality of Remedios, situated roughly 10 km southeast of the Segovia mines.

The Marmato Project contains total estimated resources of roughly 8 million ounces of gold and almost 38 million ounces of silver positioned in the Caldas department in the heart of the Middle Cauca gold district. The Marmato Project has first-rate infrastructure, being located by the Pan American Highway with access to Medellin to the north and Manizales to the south. It has access to the national electricity grid which runs near the property.

Gran Colombia Gold also has its Zancudo project. The Zancudo project is in the Titiribí mining district of Antioquia. It consists of an historical gold mine, the Independencia Mine, in the Middle Cauca Gold Belt, which produced approximately 130,000 ounces of gold with recovered grades of 14.6 g/t Au and 108.4 g/t Ag.

This past April, Gran Colombia Gold announced that it has identified additional high-grade intercepts over broad widths in the final eight holes of the infill drilling program started in 2018 on the Deeps Zone at its 100 percent-owned Marmato Project in Caldas, Colombia. The 2018 drilling campaign was undertaken to obtain more information in conjunction with the continuing technical studies and evaluations centered on the potential expansion of the underground mining operations at Marmato to incorporate the Deeps Zone below the existing mining operation, including the conversion of Inferred Resources to Indicated Resources.

Gran Colombia Gold set a new record in Q1 of 2019 with total gold production of 60,601 ounces. This is up 15 percent over Q1 of 2018. Revenue reached $77.5 million in Q1 of 2019. This is up 20 percent over the first quarter last year. The Company reported Net Income for Q1 of 2019 of $7.9 million, or $0.16 per share, versus $5.4 million, or $0.25 per share, in Q1 last year.

Gran Colombia Gold Corp. (TPRFF), closed Monday's trading session at $2.73, up 6.61%, on 26,683 volume with 42 trades. The average volume for the last 3 months is 19,501 and the stock's 52-week low/high is $1.566/$3.44.

Egalet Corporation (ZCOR)

Zacks, OTC Markets, StockRow, Street Insider, Stock Target Advisor, Stockhouse, Investor Room, Marketbeat, and Stockwatch reported previously on Egalet Corporation (ZCOR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A commercial-stage life sciences company, Egalet Corporation is presently focused on marketing its portfolio of products for pain and inflammation. Egalet is changing its name to Zyla Life Sciences. The name change reflects an intention to shift its emphasis from an abuse-deterrent technology company to a broader commercial life sciences business dedicated to bringing important products to patients and healthcare providers. Egalet Corporation is based in Wayne, Pennsylvania.

Egalet’s portfolio includes seven products: SPRIX® (ketorolac tromethamine) Nasal Spray, ZORVOLEX® (diclofenac), VIVLODEX® (meloxicam), TIVORBEX® indomethacin), INDOCIN® (indomethacin) suppositories, INDOCIN® oral suspension and OXAYDO® (oxycodone HCI, USP) tablets for oral use only —CII. To augment its product portfolio, Egalet is looking to acquire additional product candidates or approved products to develop and commercialize.

Egalet is mainly centered on commercializing non-narcotic and abuse-discouraging products. Its plan is to continue to grow revenue of its seven commercial products and explore business development opportunities. The Company has a pipeline of development-stage products and platform technology that it may look to partner or develop in the future.

Last month, Egalet reported financial results for Q1 ended March 31, 2019. Mr. Bob Radie, President and Chief Executive Officer of Egalet, said, "In late January, we closed the acquisition of five new products, completed the necessary field training and began promotion of the acquired products resulting in our portfolio of medicines generating $17.6 million in net product sales in the first quarter of 2019. That sales number reflects the expanded product portfolio in two of the three months of the quarter…”

Egalet’s Net Income for the three months ended March 31, 2019 was $96.8 million versus a Net Loss of ($12.4) million for the three months ended March 31, 2018. The increase in Net Income was driven by the gain as a result of the reorganization. The gain from reorganization was $114.6 million for the three months ended March 31, 2019.

Egalet has expanded its sales force to 87 and has started the promotion of acquired assets. The Company sold the rights to the Parvulet technology platform to Adare Pharmaceuticals. Using commonly used pharmaceutical excipients, the Parvulet technology enables the single-dose formulation of taste-masked, easy-to-swallow oral medications with a soft food like texture for pediatric and geriatric populations (including those with dysphagia).

Egalet Corporation (ZCOR), closed Monday's trading session at $2.50, down 1.96%, on 6,160 volume. The average volume for the last 3 months is 14,634 and the stock's 52-week low/high is $2.46/$3.05.

Great Bear Resources Ltd. (GTBDF)

Streetwise Reports, Stockhouse, Investing News, Metals News, Connecting Investor, Stockwatch, Mining Capital, Junior Mining Network, Wallet Investor, and Street Insider reported previously on Great Bear Resources Ltd. (GTBDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A mineral exploration company, Great Bear Resources Ltd. engages in the acquisition and exploration of mineral properties in Canada. It holds interests in the Dixie property, which is located roughly 15 minutes' drive along Highway 105 from downtown Red Lake, Ontario. The Red Lake mining district has produced greater than 30,000,000 ounces of gold. It is one of the premier mining districts in Canada. Incorporated in 2001, Great Bear Resources is headquartered in Vancouver, British Columbia.

The Dixie property covers a drill and geophysically defined 10 kilometer gold mineralized structure alike to that hosting other producing gold mines in the district. At the Dixie Project, gold mineralization is confirmed along a 2.3 km strike of a 10 km target. The system at Dixie has a high-grade gold zone that includes recent intervals of 16.35 meters of 26.91 g/t gold and 7.00 meters of 68.76 g/t gold and is open along strike and at depth.

Great Bear Resources is also earning a 100 percent royalty-free interest in the West Madsen, Pakwash, Dedee and Sobel properties. These cover regionally significant gold-controlling structures and prospective geology. The West Madsen project consists of two claims blocks, the easternmost (Block A) is now directly contiguous to Pure Gold Mining’s Madsen property. Each block is approximately six kilometers by three kilometers in size, for a total area of 3,860 hectares.

Recently, Great Bear Resources reported the discovery of a new gold control within its Dixie Limb Zone (DL) target associated with thickened and higher-grade gold mineralization. The new discovery enhances the DL as a significant potential host of high-grade gold. The DL is the original gold discovery at the Dixie project, made by Teck Resources. It is located about 200 meters to the north of, and is sub-parallel to, Great Bear's 2018 high-grade gold discovery at the Hinge Zone (DHZ).

Last month, Great Bear Resources reported drill results from the Dixie Hinge Zone (DHZ) and other new gold zones at its 100 percent owned Dixie Project in the Red Lake District of Ontario. Great Bear Resources drilled deeper in the Hinge Zone - 28.37 g/t Gold over 3.70 m, including 200 g/t Gold over 0.5 m.

Chris Taylor, President and Chief Executive Officer of Great Bear Resources, said, "With 28 meter and 100 meter step-downs continuing to hit high grade gold mineralization, the DHZ discovery yields something exceedingly rare in our industry: the more Great Bear drills it, the more compelling the target becomes."


Great Bear Resources Ltd. (GTBDF), closed Monday's trading session at $2.86, up 0.02%, on 89,034 volume with 121 trades. The average volume for the last 3 months is 40,236 and the stock's 52-week low/high is $0.3537/$3.089.

MRI Interventions, Inc. (MRIC)

Street Insider, TipRanks, EarningsCast, YCharts, Equity Clock, 4-Traders, Last10k, Market Screener, Wallet Investor, Stockhouse, InvestorsHub, Simply Wall St, Trading View, and Proactive Investors reported previously on MRI Interventions, Inc. (MRIC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

MRI Interventions, Inc. creates innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. A medical device company, it develops and commercializes unique platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or MRI guidance. The Company is developing products designed for navigation, ablation, deep brain stimulation, biopsy, aspiration and gene therapy. MRI Interventions is headquartered in Irvine, California.

The Company has two product platforms: the ClearPoint® system and the ClearTrace system. Its ClearPoint® system is in commercial use. It is used to perform minimally invasive surgical procedures in the brain.

The ClearTrace system is still in development. It will be used to perform minimally invasive surgical procedures in the heart. Both systems use intra-procedural magnetic resonance imaging to guide the procedures. The design of both systems is to work in a hospital’s existing MRI suite.

MRI Intervention’s belief is that its ClearPoint system may enable physicians to treat patients who otherwise may not be treated using present surgical techniques. In addition, by providing direct, intra-procedural visualization, the Company believes its ClearPoint system could reduce the amount of time needed to perform procedures and enable physicians to treat more patients in a given period of time.

Recently, PTC Therapeutics, Inc. (PTCT) and MRI Interventions announced a strategic equity investment, with PTC purchasing $4.0 million in shares of MRI Interventions common stock. Additionally, PTC and MRI entered into a supply agreement for MRI's neurosurgical devices for PTC's present and future gene therapy programs.

Mr. Joe Burnett, President and Chief Executive Officer of MRI Interventions, said, "We are thrilled to bring on a new partner, especially one of the size and scale of PTC Therapeutics. They have a formidable team of scientists and researchers who have accepted the challenge of treating the most debilitating neurological disorders. We look forward to contributing to their CNS gene therapy portfolio from the standpoint of device navigation and delivery and believe that working together we will achieve better outcomes and better care for the patients suffering from these challenging diseases."

MRI Interventions, Inc. (MRIC), closed Monday's trading session at $3.25, even for the day, on 1,200 volume with 4 trades. The average volume for the last 3 months is 16,923 and the stock's 52-week low/high is $1.33/$3.737.

Flower One Holdings, Inc. (FLOOF)

Trading View, InvestorsHub, The Street, Street Insider, New Cannabis Ventures, Investing News, GlobeNewswire, Morningstar, GuruFocus, The Cannabis Investor, Barchart, Seeking Alpha, Nasdaq, Dividend Investor, and reported on Flower One Holdings, Inc. (FLOOF), and today are highlighting the Company, here at the QualityStocks Daily Newsletter.

Flower One Holdings, Inc. is the owner of Nevada's largest cannabis cultivation and production facility. The Company works to leverage the industry's top agricultural technologies, using unique growing and sustainability practices to cultivate high-quality cannabis at scale for Nevada's increasing cannabis market. Flower One Holdings is based in Toronto, Ontario and the Company lists on the OTC Markets’ OTCQB.

Flower One’s mission is to build a recognizable international brand. It aims to do so while maintaining an agile approach to customized orders of cannabis flower and cannabis derivatives. The Company has the largest commercial scale greenhouse in Nevada. It is licensed for medical marijuana cultivation and production, and recreational marijuana cultivation and production in Nevada.

Upon being canopied, schedule for Q1 of 2019, the 455,000 square foot facility will be used for cannabis cultivation. It will also be used for the processing, production and high-volume packaging of dry flower, cannabis oils, concentrates and infused products. When Flower One’s greenhouse is completely operational this year, along with its indoor facility, it will be able to produce 140,000 pounds (62,500 kilograms) per year. Its state-of-the-art greenhouse and production facility are strategically situated close to the fast-growing, tourism-driven Las Vegas recreational and medical cannabis market.

Flower One announced this past January a new licensing agreement and Brand Partnership for cannabis-product fulfillment in Nevada. Palms is a California-based, experience-driven cannabis brand. Flower One is now licensed to manufacture, distribute and sell Palms' signature cannabis products to all cannabis retailers in Nevada. This marks the consumer brand's first out-of-State expansion.

Flower One Holdings announced in January another new licensing agreement and Brand Partnership for cannabis-product fulfillment in Nevada. HUXTON is an Arizona-based lifestyle cannabis brand. It is known for its curated, consistent, multi-strain blended products. Flower One is now licensed to manufacture, distribute and sell HUXTON's signature cannabis products to all cannabis retailers in Nevada. HUXTON's three product series, HIFI, RISE, and ZEN, will be available in Nevada dispensaries as pre-rolls and vape pens. They will be branded according to the experience they offer.

Recently, Flower One announced a new long-term licensing agreement and brand partnership with CannAmerica Brands Corp. for cannabis-product fulfillment in Nevada. CannAmerica Brands is a Colorado-based, marine-veteran-founded cannabis brand known for its line of top-tier cannabis gummies and edibles. Flower One is now licensed to manufacture, distribute and sell CannAmerica Brands' signature cannabis Fruit Juice Gummies and Super Soft Gummies to all cannabis retailers in Nevada. The agreement represents Flower One's official launch into the edibles market.

Flower One also recently announced a new long-term licensing agreement and partnership with foremost cannabis technology and hardware brand, Grenco Science (G Pen). Grenco Science (California headquartered) are pioneers in the cannabis hardware space, responsible for engineering the advanced technology behind the internationally-available and ever popular G Pen line of cannabis vaporizers. Flower One is now licensed to sell, distribute and integrate G Pen's proprietary, unique hardware with new cannabis products from its varied portfolio of Brand Partners.

Flower One Holdings, Inc. (FLOOF), closed Monday's trading session at $2.11, up 8.21%, on 71,155 volume with 92 trades. The average volume for the last 3 months is 108,855 and the stock's 52-week low/high is $0.879/$2.81.

MariMed, Inc. (MRMD)

NetworkNewsWire, MicroSmallCap, Wallet Investor, Insider Financial, Profit Confidential, Last10k, Stockhouse, The Street, Insider Financial, Otc.Watch, Barchart, GlobeNewswire, Simply Wall St, Proactive Investor, Investors Hub, Capital Cube, Investor Place, Marketbeat, MMJ Observer, GuruFocus, OTC Markets, Daily Marijuana Observer, Seeking Alpha, and MarketWatch reported earlier on MariMed, Inc. (MRMD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

MariMed, Inc.  is an industry leader in the design, development, operation, funding, and optimization of medical cannabis cultivation and production centers and dispensaries. The Company provides turnkey solutions to cannabis cultivators, producers, and dispensaries. It specializes in solutions for securing and operating facilities, manufacturing and processing, dispensary, layouts, and designs, merchandising and sales. MariMed has its corporate headquarters in Newton, Massachusetts. The Company lists on the OTC Markets Group’s OTCQB.

MariMed is centering exclusively on serving the fast developing $7 billion legal cannabis industry. The Company is working to create precision dosed products to treat specific conditions. Its team has developed state-of-the-art and regulatory compliant facilities in numerous States. These facilities are replicable and scalable models of excellence in horticultural principals, cannabis production, product development, as well as dispensary operations.

MariMed  provides a comprehensive range of consulting services in the medical cannabis industry. It uses a systematic approach, from the permit and application process, to on-time operational readiness.

The Company’s services include application assistance, real estate and safe access, build-out and continuing consultation, business acceleration solutions, and physician and patient outreach. MariMed Advisors, Inc. has a portfolio of high-quality branded products, product development plans, product packaging, and product licensing opportunities. 

MariMed has its strategic investment in Sprout, an all-in-one CRM and marketing software company for marijuana dispensaries and cannabis brands. MariMed’s intention is to expedite the growth of Sprout’s client base through marketing it to the leading dispensaries and cannabis companies in the U.S.

Recently, MariMed announced the creation of MariMed Hemp, Inc., a wholly-owned subsidiary to be completely centered on hemp-derived CBD products. MariMed Hemp will have a dedicated executive team, proprietary brand and product lines, and distribution and marketing relationships. These will all be separate from MariMed’s core cannabis business.

MariMed Hemp is building a full stack business to offer hemp-derived CBD products for the American market. The initial emphasis for the new venture will be to develop strong distribution networks with national reach. This will enable representatives to call on thousands of medical offices, wellness centers, and other distribution points throughout the nation. In addition, MariMed Hemp will develop a direct response gateway for sales direct to consumers.

MariMed also recently announced an agreement with Ilo™ Vapor. With this agreement, MariMed is an exclusive distributor of the company’s flagship product, DabTab™ brand dablets. This product is currently available to all cannabis dispensaries in Maryland. It will be introduced to Rhode Island, Massachusetts and Delaware dispensaries later this spring.

MariMed, Inc. (MRMD), closed Monday's trading session at $2.765, down 1.95%, on 189,173 volume with 394 trades. The average volume for the last 3 months is 260,439 and the stock's 52-week low/high is $3.00/$10.00.

biOasis Technologies, Inc. (BIOAF)

Venture Beat, Proactive Investors, Stock News Now, MarketWatch, PennyStocks24, Tailwinds Research Group, Midas Letter, GuruFocus, Capital Cube, Zacks, OTC Markets Group, 4-Traders, Stockwatch, SmallCapFinancialWire, YCharts, The Street, and Uptick Newswire reported previously on biOasis Technologies, Inc. (BIOAF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

biOasis Technologies, Inc. centers on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The delivery of therapeutics across the BBB represents the single greatest challenge in treating neurological disorders. The Company is developing and commercializing the xB3 platform, its proprietary blood-brain barrier delivery technology, to address unmet medical needs in the treatment of central nervous system (CNS) diseases and disorders. A biopharmaceutical business and OTCQB-listed, biOasis Technologies is headquartered in Richmond, British Columbia.

biOasis Technologies’ Transcend Platform is now available to be licensed by biotechnology and pharmaceutical companies for the advancement of their neurotherapeutic programs. The Transcend Platform has realized a considerable high level of success in dozens of studies at greater than 20 third-party institutions and pharmaceutical companies.

biOasis Technologies and BioAgilytix have a strategic collaboration to partner on the development and validation of bioanalytical methods to support and advance the xB3 TM-001 program, BiOasis’ lead candidate to treat HER2+ brain cancer, to investigational new drug (IND) submission and into the clinic. BioAgilytix is a leading provider of contract bioanalytical testing services with a specialization in large molecule bioanalysis.

biOasis Technologies has obtained full patent protection for its Transcend group of peptide carriers and linkers. The Transcend-peptide platform is currently referred to as the aforementioned xB3 platform. It is part of biOasis’ patented portfolio that is transforming therapeutic brain-drug delivery.

The Transcend Platform comprises a varied set of peptide carriers and linkers. These, together, provide transport solutions for a variety of CNS therapeutics. These include monoclonal antibodies, enzymes, small molecules, as well as different types of gene therapies. Transcend is founded on the naturally occurring human transport protein, melanotransferrin, also called MTf, CD228 and p97. MTf is found at low concentrations in the blood.

MTf is able to cross the BBB via a process called Receptor Mediated Transcytosis where MTf molecules attach to receptors on the cells of the BBB and is then pulled through the cells and into the brain. With the Company’s proprietary Transcend carrier, the MTf protein can be attached to therapeutics of different sizes and types.

Recently, BiOasis Technologies announced that its Board Of Directors appointed Dr. Deborah A. Rathjen as President and Chief Executive Officer. Dr. Rathjen is a member of the Board and has served as Executive Chair since December 10, 2018.

Mr. David M. Wurzer, lead independent Director, said, “Deborah has significant experience in company building and financing, mergers and acquisitions, therapeutic product research and development, business development, licensing and commercialization. Her skills and track record, combined with her recent experience working closely with BiOasis management in her capacity as executive chair, put her in a strong position to assume leadership of company. I am delighted that Deborah has agreed to become our new CEO and look forward to continuing to work with her in this new role.”  

biOasis Technologies, Inc. (BIOAF), closed Monday's trading session at $0.24935, up 18.26%, on 12,225 volume with 8 trades. The average volume for the last 3 months is 7,788 and the stock's 52-week low/high is $0.20/$0.62.

NeuroOne Medical Technologies Corporation (NMTC)

The Stock Market Watch, YCharts, Stockopedia, Penny Stock Hub, OTC Markets, Street Insider, Trading View, Wallmine, Marketbeat, Business Insider, InvestorsHub, and 4-Traders reported earlier on NeuroOne Medical Technologies Corporation (NMTC),  and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NeuroOne Medical Technologies Corporation concentrates on improving surgical care options and outcomes for patients suffering from neurological disorders. The Company is changing the landscape of surgical care for neurological disorders through the development of high-definition, minimally invasive diagnostics and treatments. OTCQB-listed, NeuroOne Medical Technologies is based in Eden Prairie, Minnesota.

In 2017, the Company completed early feasibility testing for depth electrode and combination diagnostic/ablation depth electrode. In addition, it created its Physician Advisory Board. NeuroOne centers on the development and commercialization of thin film electrode technology for cEEG and sEEG recording, brain stimulation and ablation solutions for patients suffering from Epilepsy, Parkinson’s Disease, Dystonia, Essential Tremors and other related brain related disorders.

The Company believes that technology in its pipeline can improve outcomes through reducing the risk of infection; decreasing inflammation of the brain during recording; and increasing accuracy and specificity of recorded brain activity. Furthermore, NeuroOne believes that technology in its pipeline can improve outcomes through minimizing invasiveness of the procedure; and reducing time-consuming, cumbersome, and expensive technical use and management within facilities. NeuroOne’s emphasis is on the development and commercialization of Diagnostic Recording and Therapeutic Modalities.

At present, the chief goals for NeuroOne Medical Technologies are to file patent application(s) based on the submitted 2017 provisional patents, and complete pre-clinical study for its diagnostic and diagnostic/ablation combination depth electrode. Moreover, main goals include ramping up production and continuing to strengthen its Physician Advisory Board where appropriate.

Recently, NeuroOne Medical Technologies announced the hiring of Mrs. Leah Noaeill as Senior Director of Marketing and Mr. Scott Heuler as Vice President of Sales to establish NeuroOne’s U.S. commercial organization and drive any future product launches. Mrs. Noaeill comes to the Company with 15 years in medical device marketing in a connected healthcare environment. Most recently, she worked at Smiths Medical leading the Infusion Software marketing and application support teams.

Mr. Heuler comes to NeuroOne Medical Technologies with more than 25 years in sales management, marketing and senior leadership positions in the medical device industry. Mr. Heuler’s background includes regional and senior sales positions with Boston Scientific Corporation in Interventional Cardiology, Structural Heart, Cardiac Rhythm Management and Peripheral Vascular. Before this, he held various senior sales and marketing roles with Guidant Corporation and U.S. Surgical Corporation.

NeuroOne Medical Technologies Corporation (NMTC), closed Monday's trading session at $3.49, up 5.12%, on 1,580 volume with 6 trades. The average volume for the last 3 months is 8,246 and the stock's 52-week low/high is $3.00/$10.00.

eMarine Global, Inc. (EMRN)

RedChip, MarketWatch, OTC Markets, Financial Content, GuruFocus, Last10k, Morningstar, Stockopedia, Wallmine, Simply Wall St, Dividend Investor, Stockhouse, Teletrader, Marine Insight, Capital Cube, Street Insider, The Street, Parker City News, Wallet Investor, GlobeNewswire, Nasdaq, InvestorsHub, Barchart, YCharts, Insider Mole, and Stockwatch reported earlier on eMarine Global, Inc. (EMRN), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

eMarine Global, Inc. is a foremost provider of information and communications technology (ICT) for the maritime industry. The Company provides solutions for collection, integration and display of maritime information abroad and ashore via electronic means to enhance berth to berth navigation and related services.

Incorporated in 2001, eMarine Global has its corporate headquarters in Ulsan, South Korea. The Company lists on the OTC Markets’ OTCQB. It previously went by the name Pollex, Inc. It changed its name to eMarine Global, Inc. in August of 2017.

eMarine Global’s solutions provide the most efficient means to secure the safety of life at sea and to protect the marine environment. All products and services offered by the Company are through subscription, installation, updates and/or maintenance contracts.

eMarine Global offers electronic chart display and information systems (ECDIS) - a computer-based navigation system provides navigational information. The Company also offers electronic navigation charts (ENC) that integrates position information from the global positioning system (GPS) and other navigational sensors. In addition, eMarine provides smart chip solutions, including intra-ship integrated gateway (ISIG), an intra-ship network; collision avoidance and optimal voyage systems; and remote maintenance and engine monitoring systems.

Recently, eMarine Global announced it secured a three-year contract with Hyundai Global Service Co., Ltd. (a spin-off of Hyundai Heavy Industries) to supply the Company’s Marine Internet-of-Things (IoT) platform for over 1,000 ships presently in operation at sea. eMarine Global’s newly developed Marine IoT platform will enable Hyundai to remotely monitor the real-time operation of its ships. This will provide the necessary data to propel proactive and pre-emptive repair and maintenance decisions that will ultimately lead to more efficient operations.

eMarine Global was recently recognized as a top solution provider and for its contributions to the local economy in Ulsan during a recent visit by the Deputy Minister of Science and ICT to eMarine’s Ulsan R&D center. The Deputy Minister was accompanied by the heads of Ulsan and national ICT promotions, and also Ulsan city officials.

eMarine Global also recently announced it was awarded a contract to supply its Warship-ECDIS (Electronic Chart Display & Information System) for 20 Republic of Korea Navy vessels. The contract is valued at 500 million Won ($500,000). The Company will supply the warship version of its ECDIS to 10 navy destroyers and 10 support ships. The support ship installations will be equipped aboard newly built vessels. This includes port guard boats and fuel barges. The 10 destroyer installations are replacement orders to retrofit earlier outfitted vessels.

Ung Gyu Kim, Chairman and Chief Executive Officer of eMarine Global, said, “We’re now reaching the replacement cycle for some of the earliest installations of our Warship-ECDIS for the navy and other government customers. We’ve supported these systems, on 215 naval ships, for the last nine consecutive years, placing us in a great position as a trusted solution partner.”

eMarine Global, Inc. (EMRN), closed Monday's trading session at $1.00, up 25.00%, on 340 volume with 2 trades. The average volume for the last 3 months is 858 and the stock's 52-week low/high is $0.40/$10.00.

Altamira Gold Corp. (EQTRF)

Capital Equity Review, Stockscores, Spotlight Growth, 4-Traders, StreetWise Reports, Junior Mining Network, Seeking Alpha, Barchart, InvestorX, Stockwatch, MarketWatch, Stockhouse, The Street, GuruFocus, Wallet Investor, and Barchart reported beforehand on Altamira Gold Corp. (EQTRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Altamira Gold Corp. engages in the acquisition, exploration, development, and mining of mineral properties in Canada and Brazil. A junior natural resource enterprise, the Company previously went by the name Equitas Resources Corp. It changed its corporate name to Altamira Gold Corp. in April 2017. Altamira Gold is headquartered in Vancouver, British Columbia and the Company lists on the OTC Markets.

Altamira Gold is concentrating on the exploration and development of gold deposits within the Juruena belt of western Brazil. The Company has a Brazil focus. Altamira has 12 license areas consisting of 200,000-plus ha in the prolific Juruena gold belt (7–10M oz of artisanal gold production).

Altamira Gold also has its advanced Cajueiro Project. This project has
an NI 43-101 (National Instrument 43-101) resource of Indicated Resources of 214,000 oz Au and Inferred Resources of 204,000 oz Au plus an additional
79,000 oz at 1.61 g/t Au in oxides (as Saprolite). Two new zones were discovered at the Cajueiro Project in 2017. The two new zones discovered are at Baldo East and Toninho.

In addition, the Company has its Crepori Project. This Project is 8,323 ha with historical small-scale production. The Crepori Project is 105 km SSW of Eldorado Gold’s TZ Project. Surface sampling at Crepori has returned values up to 1022.98 g/t gold with about 10 percent of surface samples returning +5 g/t gold.

Altamira Gold reported this past December that it successfully applied to claim a strategic land position within the Alta Floresta Belt. The new claims total 70,184.70 hectares. They lie on the northern margin of the Alta Floresta Belt close to the contact with the sediments of the Cachimbo Graben. Altamira Gold's total land position in the belt is now more than 300,000 hectares.

Recently, Altamira Gold reported that it was granted an additional 42,000ha within the Apiacas district in Brazil, situated close to the northern margin of the Alta Floresta Belt. Highlights include the granting of 42,000ha at Apiacas bringing the total land position controlled by Altamira Gold at Apiacas to 82,000ha. This includes the highly prospective Mutum target characterized by widespread phyllic alteration and disseminated pyrite.

Recent surface sampling by the Company returned gold values ranging from 9.0 to 46.1 g/t gold from 9 grab samples of a total of 17 samples from the Paulinho Troca-Tiro target. Highlights also include recognition of extensive disseminated gold mineralization associated with hydrothermal alteration over several square kilometers at the Mutum target.

Altamira Gold Corp. (EQTRF), closed Monday's trading session at $0.0718, up 10.46%, on 27,995 volume with 15 trades. The average volume for the last 3 months is 4,706 and the stock's 52-week low/high is $0.041313/$0.1238.

BioElectronics Corporation (BIEL)

Microcap Daily, Central Charts, Pink Investing, Uptick Newswire, Wallet Investor, Emerging Growth, Clay Trader, Street Register, Stockhouse, MarketWatch, Investors Hangout, StreetInsider, Barchart, Biospace, InvestorsHub, Market Screener, and Morningstar reported beforehand on BioElectronics Corporation (BIEL), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

BioElectronics Corporation is a leader in non-invasive electroceuticals. The Company is the maker of an industry leading family of disposable, drug-free, pain therapy devices. Its unique medical devices safely and effectively treat chronic and acute pain via an innovative mechanism of non-invasive sub-sensory neuromodulation. BioElectronics has its corporate office in Frederick, Maryland.

BioElectronics’ products include RecoveryRx® and ActiPatch®. RecoveryRx® uses pulsed electromagnetic therapy to lessen pain and inflammation resulting in accelerated patient recovery and improved comfort. For medical professionals, the RecoveryRx® medical device provides a safe and cost-effective pain management therapy.

ActiPatch® provides advanced long-lasting chronic pain relief using Electromagnetic Pulse Therapy. It is a new and clinically proven drug free technology in the battle against chronic pain. 

The Company’s products also include Smart Insole™, Allay® Menstrual Pain Relief, and HealFast® Veterinary Pain Relief. HealFast® Therapy is a drug-free therapy for horses, cats and dogs. It decreases swelling and pain while it hastens the healing of muscle and tendon injuries, sores, and incisions.

Allay® is an award-winning drug-free micro medical device. It uses Electromagnetic Pulse Therapy to lessen menstrual pain and discomfort. The Smart Insole™ consists of Electro-Pulse micro medical devices. These are embedded in comfortable heel gel inserts.

Recently, BioElectronics announced that two Traditional 510(k) Premarket Notification applications were filed with the U.S. Food and Drug Administration (FDA). These applications were for the ActiPatch® and RecoveryRx® medical devices for market clearances of “over-the-counter adjunctive treatment of musculoskeletal pain in women”, and “over-the-counter adjunctive treatment of postoperative pain”, respectively.

Mr. Keith Nalepka, VP of Sales/Marketing, said, “Obtaining musculoskeletal and postoperative pain clearances will make ActiPatch and RecoveryRx devices available to more than 100 million Americans seeking safe, drug-free pain relief.”

BioElectronics also recently announced the start of a clinical study investigating the efficacy of ActiPatch in treating chronic lower back pain. The goals of this additional back pain study are to support Mundipharma’s Australia and New Zealand sales and marketing, provide local economic data for product reimbursement, and to document ActiPatch’s effectiveness on central sensitization pain.

This study is being conducted by the Pain Management Center of the prestigious Royal Prince Alfred Hospital in Sydney, Australia. The principal investigator (PI) leading the study is Mr. Graeme Campbell, a physiotherapist, supported by his team of physicians and clinical researchers.

BioElectronics Corporation (BIEL), closed Monday's trading session at $0.0008, up 14.29%, on 107,121,984 volume with 58 trades. The average volume for the last 3 months is 36,005,506 and the stock's 52-week low/high is $0.0005/$0.004.

The QualityStocks Company Corner

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight diseases, will share results of recent clinical advancements at the upcoming Ninth Annual LD Micro Invitational scheduled to take place at the Luxe Sunset Boulevard Hotel, June 4-5 in Bel-Air, California. Co-founder and CFO David Moss will lead INmune Bio’s presentation, which is set for June 5 at 10:20 a.m. PT, and participate in one-on-one meetings at the event, according to a news release (

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

  • Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
  • Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
  • Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.


Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed the day's trading session at $10.35, up 0.98%, on 4,575 volume with 50 trades. The average volume for the last 3 months is 17,914 and the stock's 52-week low/high is $7.00/$11.50.

Recent News

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element, Inc. (NASDAQ: NETE) ("Net Element" or the "Company"), a global technology and value-added solutions group that supports electronic payments acceptance in a multichannel environment including point-of-sale (POS), e-commerce and mobile devices, today announces that it has launched Blade, its proprietary, fully-automated, artificial intelligence (“AI”)-powered underwriting solution with predictive scoring.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

With an eye on emerging markets, Net Element is pursuing growth opportunities and footholds in a number of industries. The company’s most recent application of its technology is to the cannabis industry, which is paced to hit $591 million and could increase 40 times in the next four years. This rampant growth also creates heightened need for smooth transactions between merchants and consumers. Payment processing and compliance for the cannabis industry has become increasingly complex, and Net Element’s Unified Payments subsidiary is addressing the challenges by offering a compliant, seamlessly integrated payment solution that makes it simple to transact.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $4.08, up 3.55%, on 11,442 volume with 84 trades. The average volume for the last 3 months is 45,504 and the stock's 52-week low/high is $3.75/$10.60.

Recent News

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (OTC: STLHF).

Standard Lithium Ltd. (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L), is pleased to provide an update regarding the ongoing fabrication of the Company’s lithium extraction Demonstration Plant.  The plant, being constructed by Zeton Inc. is nearing completion, and Phases 1 and 2 are 92% complete.  The current schedule shows that fabrication and all associated piping, electrical and control systems of Phases 1 and 2 will be completed by early Q3/19.  Upon completion, the Phase 1 and 2 modules will be disassembled and trucked to the in-field location at Lanxess’ South Plant facility in southern Arkansas.

Standard Lithium Ltd. (OTC: STLHF) is focused on unlocking the value of existing large-scale U.S.-based lithium brine resources that can quickly be brought into production. The Company believes new lithium production can rapidly be brought on stream by minimizing project risks at selection stage; resource, political & geographic, and regulatory & permitting; and by leveraging advances in lithium extraction technologies and processes.

The Company’s flagship project is in southern Arkansas. The more than 180,000-acre “Smackover Project” is in the most prolific and productive brine processing region in North America. Agreements with large commercial brine operators in the region will allow Standard Lithium to utilize the extensive existing infrastructure, including brine supply and disposal pipelines, water, power and a trained workforce to fast-track project development timelines.

“Arkansas produces about 9.4 billion gallons of brine per year, according to 2010-2016 average statistics reported by the Arkansas Oil & Gas Commission.”

Standard Lithium signed a binding MoU with global specialty chemicals company LANXESS Corporation and its U.S. affiliate Great Lakes Chemical Corporation with the purpose of demonstrating the commercial viability of extraction of lithium from brine (“tail brine”) that is produced as part of LANXESS’ bromine extraction business at its three Southern Arkansas facilities.

LANXESS’ land operations in Southern Arkansas encompass more than 150,000 acres, 10,000 brine leases and surface agreements and 250 miles of pipelines. LANXESS extracts the brine from its wells located throughout the area, and the brine is transported to the three Arkansas plants through a network of pipelines. The three bromine extraction plants currently employ approximately 500 people and process and reinject several hundred thousand barrels of brine per day.

Standard Lithium has developed a breakthrough rapid lithium extraction process that reduces the recovery time of extracting lithium from brine to as little as several hours vs. the current industry method that takes years. The process is also much more environmentally friendly with a significantly smaller footprint than the conventional processes. The company has a signed agreement to locate a demonstration scale lithium extraction plant inside one of LANXESS’ chemical plants in Southern Arkansas.

The Company has also signed an option agreement with NYSE-listed Tetra Technologies for the lithium rights for exploration, extraction, and possible commercial development on approximately 30,000 acres of brine leases in Southern Arkansas. The largest available land package.

Recent laboratory results of four brine samples recovered from two existing wells in Standard Lithium’s project area showed lithium concentrations ranging between 347-461 mg/L lithium, with an average of 450 mg/L lithium in one of the wells and 350 mg/L in the other. Geological modeling of the project area is complete, and a maiden resource report is on the horizon.

Market Opportunity

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.


Standard Lithium’s commitment to being a premier, innovation-driven company focused on developing and commercializing new modern processes for lithium extraction is bolstered by the leading experts that comprise the company’s Scientific Advisory Council. Each member was selected because of their experience and expertise in areas that are central to and/or complement Standard Lithium’s current development plans. Standard Lithium recently welcomed to the Council world-renowned chemist Dr. Barry Sharpless, the recipient of the 2001 Nobel Prize in Chemistry for his work on chirally catalyzed oxidation reactions.

Standard Lithium is led by a team of professionals with proven strong technical and project development skills. CEO Robert Mintak has a global network of industry contacts and is a pioneer in the rapidly evolving lithium space. COO and President Dr. Andy Robinson is an experienced geoscientist with 20+ years of experience and a PhD in Geochemistry from the University of Bristol, UK. Dr. Robinson has worked on a wide range of projects in the resource, power and energy sectors in Europe, Africa, and North and South America.

The company recently appointed Robert Cross as non-executive chairman. Cross is an engineer with 25 years of experience as a financier and company builder in the mining and oil and gas sectors. He co-founded and serves as chairman of B2Gold, a top-performing growing gold producer which is expected to achieve nearly 1 million ounces of low-cost gold production in 2018. He was also co-founder and chairman of Bankers Petroleum Ltd.; co-founder and chairman of Petrodorado Energy Ltd.; and until October 2007 was the non-executive chairman of Northern Orion Resources Inc. He also was previously the chairman and CEO of Yorkton Securities Inc., and a partner in investment banking with Gordon Capital Corp. in Toronto. Cross has an engineering degree from the University of Waterloo (1982) and received an MBA from Harvard in 1987.

Following a multi-million-dollar financing in Q1 2018, Standard Lithium is well-positioned to meet its upcoming milestones including two maiden resource reports and the launch of its breakthrough rapid lithium extraction technology.

Standard Lithium Ltd. (OTC: STLHF), closed the day's trading session at $0.6122, up 4.38%, on 2,164 volume with 5 trades. The average volume for the last 3 months is 32,217 and the stock's 52-week low/high is $0.484/$1.387.

Recent News

City View Green Holdings Inc. (CSE: CVGR)

The QualityStocks Daily Newsletter would like to spotlight City View Green Holdings Inc. (CVGR).

City View Green Holdings Inc. (CSE: CVGR) trading through the facilities of the Canadian Securities Exchange ("CSE") under the symbol "CVGR" is pleased to announce that Budd Hutt Inc. ("Budd Hutt"), is currently involved in pursuing strategic retail cannabis partnerships in Alberta and across the country, including BC, SK and ON., engaging and building strong financial investment partners to fulfill the funding needs of the organization along the way. With the recent news from Alberta on May 29, 2019 ( we are excited about the next few weeks.

City View Green Holdings Inc.'s (CSE: CVGR) (formerly Icon Exploration Inc.) primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry. Icon Exploration recently signed a formal share exchange agreement relating to its proposed acquisition of privately held City View Green (“CVG”), a vertically integrated cannabis company incorporated under the laws of Ontario, Canada. CVG’s application to Health Canada for an A6ccess to Cannabis for Medical Purposes Regulations (“ACMPR”) license is now at the in-depth review stage of the licensing process.

CVG is preparing a 40,000-square-foot growing facility near Toronto to produce pharmaceutical-grade cannabis once its ACMPR license is granted. About half of the facility will initially be outfitted with state-of-the-art LED lighting, HVAC and dehumidification systems, and automation technologies to optimize the quality, safety and consistency of cannabis production. About 4,000 square feet will be devoted to an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process with plans to include ethanol extraction technology in the future.

Another 4.3 acres remains available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates, and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.


Icon and CVG have assembled a talented team that includes a Master Grower with cannabis-industry experience to manage indoor grow operations and an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. Having gained experience in the Washington state market the extraction expert has a number of brand ideas and recreational cannabis products that became popular in the Washington market as well as a number of in-licensing branding opportunities available to CVG. CVG has also negotiated an agreement with a private company seeking 37 retail cannabis licenses in Alberta, Canada, that provides a reciprocal exchange of shares, product, shelf space and distribution lines. Early discussions with various entities in Europe to arrange an off-take agreement for CBD oils and extracts are also underway.

Market Opportunity

The Canadian medical cannabis market has steadily been growing with an average 10 percent increase in patients each month. Now that the Canadian federal government has legalized recreational cannabis for adult users nationwide, analysts project a compound annual growth rate of nearly 78 percent from 2018 to 2021, reaching an estimated $3 billion by 2021, ArcView Market Research reports. One study from Deloitte pegged the potential economic impact of legalized medical and recreational marijuana in Canada – including transportation, licensing fees and security – at more than $22 billion over the coming years. Health Canada’s most recent data show that sales of cannabis extracts grew 961 percent in the second quarter of 2017, compared to an 89 percent increase in growth of dried cannabis during the same period.

City View Green Holdings Inc. (CSE: CVGR), closed the day's trading session at $0.12, even for the day, on 125,000 volume with 18 trades. The average volume for the last 3 months is 343,190 and the stock's 52-week low/high is $0.096/$0.465.

Recent News

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

At the end of April, OrganiGram Holdings (TSXV:OGI) (NASDAQ:OGI) filed all the necessary paperwork with the NASDAQ in hopes of uplisting to the major exchange. Three weeks later, on May 21, OrganiGram stock began trading here under the ticker OGI.

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.


Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed the day's trading session at $6.86, off by 5.25%, on 1,488,082 volume with 5,822 trades. The average volume for the last 3 months is 1,288,337 and the stock's 52-week low/high is $2.97/$8.44.

Recent News

The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF)

The QualityStocks Daily Newsletter would like to spotlight The Flowr Corporation (FLWR).

The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF), a Canadian cannabis cultivation firm, on Friday announced that the company’s CEO Vinay Tolia is scheduled to participate in a panel discussion at Piper Jaffray’s 39th Annual Consumer Marketplace Conference taking place at The Pierre New York in New York City on Thursday, June 6th. To view the full press release, visit:

The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF), a Health Canada Licensed Producer (LP) of cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR), is an emerging Canadian cannabis leader founded by Medreleaf co-founder Tom Flow and a team of industry pioneers, successful start-up executives and top industry scientists. Flowr’s purpose-built cultivation facilities may be the most advanced in the industry, consistently generating high crop yields, delivering premium and ultra-premium cannabis products, and maximizing return on investment. The company also may be an R&D leader as it was selected by the Hawthorne Gardening Division of The Scotts Miracle-Gro Company as its exclusive Canadian cannabis R&D partner.

Flowr’s flagship facility, an 84,000-square-foot campus on seven acres in Kelowna, British Columbia, is engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. This, along with exacting protocols designed by the Flowr team, enables Flowr to grow cannabis that meets Health Canada’s stringent standards without treating it with the taste- and smell-killing gamma irradiation that most other producers have to use to clean their product. Irradiating the plant – a process similar to pasteurizing food – impairs many of the important terpenes that provide the positive effects, flavors and scents of cannabis while strengthening unpleasant terpenes. Flowr’s products may deliver a better user experience, thus commanding premium prices.

Flowr’s cultivation facilities, built with proprietary, patent-pending systems, are designed to deliver yields targeted at 450 grams per square foot by the end of 2022, which is three times more efficient than the industry average of approximately 150 grams per square foot. By optimizing yield, the Company may produce significantly more cannabis flower on a smaller footprint than other producers, thus generating far high revenue per square foot and keeping costs much lower, leading to higher margins. The Kelowna facility is presently 20 percent operational with the remaining 80 percent slated to come online by early 2019. It is expected to produce up to 14,000 kg of premium, non-irradiated cannabis flower in 2019. With further enhanced yields and planned expansion of production facilities on the campus, Flowr will reach a total capacity of 60,000 kg annually in 2022.

Leading Flowr’s cultivation program is industry pioneer, company co-founder and Flowr president Tom Flow. Flow is widely recognized for his cannabis thought leadership and expertise building and operating cannabis cultivation facilities. Flow also co-founded MedReleaf and designed, built and set up SOPs for their flagship Marcum cultivation facility. Marcum has continued to be perhaps the most productive facility in the country prior to the Flowr flagship facility. Long one of Canada’s most efficient and profitable LPs, MedReleaf was acquired by Aurora for approximately C$3 billion. Flow and his team have designed and built a total of 17 cultivation facilities and secured three producer’s licenses under various Canadian regulatory regimes.

In March 2018, Flowr and the Hawthorne Gardening Division of The Scotts Miracle-Gro Company – a world leader in lawn and garden products – announced an exclusive strategic R&D alliance. After evaluating numerous Canadian LPs, Hawthorne chose to partner with Flowr based on the experience and expertise of the company’s cultivation and R&D teams and the company’s advanced growing capabilities.

Hawthorne will fund the construction of a 50,000-square-foot R&D facility that is integrated into Flowr’s Kelowna campus. This facility is North America’s first dedicated cannabis R&D facility focused on advancing cultivation techniques and systems. The facility will support researchers from both organizations and combine laboratories, indoor and greenhouse grow suites, training areas and genetics breeding areas in a single building. It is expected to open in early 2019. In addition to helping Flowr maintain its competitive advantage in cultivation, the company’s R&D program will keep it on the cutting edge of cannabis innovation.

Flowr is entering the market with three different brands to meet the growing demand for premium, non-irradiated cannabis in the medicinal and adult use markets:

  • FlowrRx, featuring premium quality medicinal cannabis that enables patients to live better, fuller lives. A dedicated Client Services team will provide patients with personalized support while an R&D team develops innovative flower strains and premium products targeted to specific conditions. Patient well-being is considered at every stage of the process – from genetic selection to harvest, trimming and curing techniques. FlowrRx and its team of passionate scientists and leading cultivation specialists are dedicated to advancing the scientific understanding of cannabis.
  • Flowr is the company’s premium recreational adult-use brand featuring an active, West Coast-inspired lifestyle for the cannabis connoisseur and enthusiast market. Through the continuous innovation of procedures and practices, Flowr’s talented team of experts is crafting premium products that deliver unparalleled experiences.
  • Ace Valley, an exclusive partnership with top-selling Ontario craft beer company Ace Hill, will bring Flowr’s premium product to the millennial and casual adult-use markets under the Ace Valley brand.

Flowr recently signed a Memorandum of Understanding with the British Columbia Liquor Distribution Branch, the province’s sole legal wholesaler of non-medical cannabis, to supply premium and ultra-premium flower to the province’s retail outlets. The company has agreements with several major medical distributors and is in discussions about retail distribution with additional provinces where it believes it can obtain prices commensurate with the quality of the Flowr products. The company is also evaluating other market opportunities including export.

Flowr is poised to become the pre-eminent indoor premium cannabis grower in Canada and one of the country’s top five LPs. The company’s focus on yield, quality and price point and its team’s ability to grow at scale should drive high margins, significant growth and strong return on investment.

The Flowr Corporation (TSX.V: FLWR), closed the day's trading session at $6.08, off by 10.59%, on 136,602 volume with 388 trades. The average volume for the last 3 months is 279,849 and the stock's 52-week low/high is $2.74/$8.42.

Recent News

TransCanna Holdings Inc. (CSE: TCAN)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

Transcanna Holdings Inc. (CSE:TCAN: XETR: TH8) (“TransCanna” or the “Company”) is pleased to announce the Company’s wholly owned subsidiary, TCM Distribution, Inc., has received an Adult Use Cannabis Manufacturing permit and an Adult Use cannabis distribution permit from the City of Adelanto, California.

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $5.55, off by 1.77%, on 47,737 volume with 92 trades. The average volume for the last 3 months is 160,800 and the stock's 52-week low/high is $0.769/$7.789.

Recent News

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), Canada’s only coast-to-coast premium cannabis producer, recently announced its entry into a definitive arrangement agreement to acquire Blissco Cannabis Corp. in an all-stock transaction worth approximately C$48 million ( Also today, the company was pleased to announce its participation at select conferences in June. Including: Lift&Co. Toronto Expo – Toronto, ON; World Cannabis Congress – Saint John, NB; IdeaCity Toronto – Toronto, ON; European Cannabis Week – London, UK.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $1.14, off by 6.33%, on 460,016 volume with 658 trades. The average volume for the last 3 months is 576,473 and the stock's 52-week low/high is $0.85/$2.04.

Recent News

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: INNPF).

Innovative Properties Inc. d/b/a Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, this morning announced its entry into an agreement to purchase 2,260,500 common shares, representing a 49% interest, of Cannova Medical Ltd., and to acquire the remaining 51 percent interest at the option of Nabis.

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."


While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: INNPF), closed the day's trading session at $0.4637, off by 3.40%, on 60,530 volume with 47 trades. The average volume for the last 3 months is 183,735 and the stock's 52-week low/high is $0.392/$0.791.

Recent News

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) today announced that its third quarter sales were up to $2.5 million, reflecting a 78% increase over the second quarter. According to the update, Wildflower sales have increased every quarter since the company began selling its popular line of hemp CBD products. To view the full press release, visit:

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.4518, off by 10.52%, on 9,466 volume with 18 trades. The average volume for the last 3 months is 22,935 and the stock's 52-week low/high is $0.009/$1.129.

Recent News (CIIX)

The QualityStocks Daily Newsletter would like to spotlight (CIIX). (CIIX) was featured today in the 420 with CNW by CannabisNewsWire. One of the best ways to learn about any subject of interest is by seeking out materials, such as documentaries, sitcoms, movies and other shows. This article summarizes some of the most acclaimed documentaries which will help you to delve into the different aspects (on both sides of the divide) of the cannabis industry.

Founded in 1999, (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website,, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site,, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. (CIIX), closed the day's trading session at $0.42, off by 7.69%, on 61,978 volume with 28 trades. The average volume for the last 3 months is 57,342 and the stock's 52-week low/high is $0.365/$1.25.

Recent News

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF)

The QualityStocks Daily Newsletter would like to spotlight Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF).

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF) was featured today in the 420 with CNW by CannabisNewsWire. One of the best ways to learn about any subject of interest is by seeking out materials, such as documentaries, sitcoms, movies and other shows. This article summarizes some of the most acclaimed documentaries which will help you to delve into the different aspects (on both sides of the divide) of the cannabis industry.

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF), an investment company focused on the U.S. and international cannabis sectors, provides turnkey solutions for the regulated cannabis industry. The company leverages managements' expertise and decades of experience in the cannabis industry to acquire and develop vertically integrated cannabis assets. Chemistree recently closed on a purchase of prospective cannabis cultivation property in California, made a first investment in the Canadian cannabis industry, owns assets in the State of Washington used to operate an established retail cannabis brand, and has an active pipeline of assets in place to grow its portfolio.

Chemistree offers industry leading expertise across all areas the cannabis business and in its growth as a public or private company.

  • Investment and funding for rapid growth
  • Vertical integration solutions
  • Construction, design and/or optimization of indoor or outdoor cultivation facilities
  • Reputation management & influencer outreach
  • Branding and Packaging
  • Social Media and Media outreach

With the marketing of cannabis companies and their products in its infancy, the company believes the industry offers tremendous opportunity for growth in the U.S. and abroad. Chemistree initially targeted the Pacific Northwest for investment and, following its recent California property purchase, expects to expand vertically across the United States in areas where it has a competitive business advantage.

Through its wholly owned CHM Desert LLC subsidiary, Chemistree owns 9.55 acres of undeveloped land in Desert Hot Springs, California. The property is zoned as Light Industrial Lands Designated for Marijuana Cultivation, and local zoning ordinances allow as a conditional use the location of up to three onsite cannabis cultivation buildings of 68,000 square feet each, along with support space that would support production of 55,000 pounds/year.

Through its wholly owned Chemistree Washington Ltd. subsidiary, Chemistree acquired physical assets used in the cultivation, production and distribution of cannabis. The Washington assets are currently under lease to Sugarleaf Farm LLC, which operates the Sugarleaf brand of retail cannabis products in the State of Washington. Sugarleaf Farm is a Tier 3 cannabis producer and processor whose products are sold in about 125 retail outlets. Chemistree has indicated the relationship with Sugarleaf may provide the company with additional opportunities to become involved in the marketing of Sugarleaf products.

Chemistree funded these acquisitions and investments with the proceeds of two non-brokered private placement financings completed earlier this year under the regulations of the Canadian Securities Exchange, totaling CAD$4.5 million. In conjunction with the private placements, the company was granted approval by the CSE for a change of business to become an Investment Issuer. This funding is expected to provide the company "maximum flexibility to take advantage of the numerous opportunities available in the cannabis industry in Canada and the U.S."

Chemistree also has a strategic investment in Pasha Brands Ltd., a British Columbia based cannabis company with multiple internationally recognized brands. Pasha has a proven history in cannabis retailing and its proposed Licensed Processing (LP) facility on Vancouver Island is in the final stage of the application for government approval. The LP facility is expected to assist in licensing selected craft growers of cannabis and expanding the distribution of locally grown product. The investment represents less than 10% of Chemistree's working capital.

Company Chairman Justin Chorbajian is co-owner of the largest chain of privately owned hydroponic retail shops in Canada. He also cofounded a group of companies that manufacture and distribute hydroponic equipment. He is a frequent contributor to Growing Exposed, the leading video series dedicated to cannabis cultivation. Company President Karl Kottmeier is a former investment advisor with 20 years of experience listing, financing and administering companies on the Toronto Stock Exchange and TSX Venture Exchange. He has raised more than $150 million in equity capital for ventures. Chemistree CFO Doug Ford has been general manager of Dockside Capital Group Inc., a private merchant banking and venture capital firm serving emerging growth companies. Sheldon Aberman, the most recent member of the Board, has managed, designed and created industry leading grow room designs around the world. Additionally, he has built several leading brands such as Frost Box and Black Label and is an expert in the accessory market (vape pens, silicon mats and extraction tools etc.).

Data firm Statista has forecast the U.S. legal cannabis market will be worth more than $24 billion by 2025. New Frontier Data, which focuses exclusively on the cannabis industry, projects the value of the Canadian domestic cannabis market that same year at CAD$9.2 billion.

Chemistree Technology Inc. (CHMJF), closed the day's trading session at $0.3474, off by 9.11%, on 141,009 volume with 100 trades. The average volume for the last 3 months is 100,931 and the stock's 52-week low/high is $0.268/$0.605.

Recent News


The QualityStocks Daily Newsletter would like to spotlight IONIC Brands Corp. (OTC: ZRRRF).

IONIC Brands Corp. (CSE: IONC) (OTC: ZRRRF) is a national cannabis holding company that’s building a multistate portfolio of award-winning premium and luxury brands in the cannabis space. Established in 2015, IONIC Brands is an industry leader with a proven ability to expand and operate multiple cannabis concentrate consumer brands in markets across the western United States.

IONIC Brands Corp. (CSE: IONC) (OTC: ZRRRF) is a national cannabis holding company building a multistate portfolio of award-winning premium and luxury brands in the cannabis space. Established in 2015, IONIC Brands has demonstrated its ability to expand and operate multiple cannabis concentrate consumer brands in markets across the western United States. The company continues to strategically expand nationwide to remain a leader of the highest-value segments in the cannabis market.

With a focus on quality, responsibility and respectability, IONIC's product lines are pioneering the changing landscape of cannabis consumption. The company's refinement practices are a result of a passionate commitment to craft the finest, small-batch cannabis oils and cannabis concentrates in the world – without glycols, glycerins or additives.

IONIC's Certified Clean program verifies that every product leaving the company's facilities meets or exceeds state mandates on pesticide testing. The testing is conducted by individually testing every batch which ensures and enhances trust and transparency. IONIC recently paired its Certified Clean program with Lucid Green Inc. and its revolutionary technology platform designed to provide vital safety information. Lucid Green's technology provides a direct-to-consumer data platform, providing instant access to a library of product specific insights by simply scanning the package's QR code with a smartphone camera.

Elite Brand Portfolio/Acquisitions

  • IONIC, the company's flagship recreational branded product, is a stylish and sophisticated premium vape pen line that has earned customer loyalty and a reputation as a consistent Top 10 vape brand in Washington state. IONIC's immediate product line expansion plans include THC/CBD mixes, low-dose products, high-end edibles, CASK oil and device innovation.
  • WW Agriculture cultivates cannabis outdoors on a 140-acre eastern Washington State farm capable of producing up to 100,000 pounds of cannabis for less than $0.10/gram.
  • ZOOTS, a Washington-based edibles company, utilizes patent-protected ultra-clean CO2 extraction hardware to create proprietary formulations of refined cannabis oils and distillates. Through MedMen dispensaries, Zoots Edibles are currently available in Washington and Colorado and will soon be on shelves at dispensaries in Massachusetts, New York and Pennsylvania.
  • Vuber Technologies hardware produces the best vaporization experience on the market.
  • Vegas M Stick vaporizer pens are distributed to stores in Washington State with plans to expand to Oregon and Nevada.
  • Vegas Valley Growers is a revenue-generating, vertically integrated operation in Las Vegas, Nevada, with a full complement of production, manufacturing and distribution licenses.

IONIC has also acquired two U.S. patents issued to Canna Café that are related to cannabinoid (CBD) infused coffee and CBD-infused coffee in a Keurig ® K-Cup ® Pod. An international patent is in process for cannabis-infused teas.

Experienced Management Team

IONIC Brands is led by an innovative product team, powerful sales organization and a world-class marketing group.

Chairman & CEO John Gorst has built and sold four different technology companies with market valuations in excess of $600 million. Gorst has been at the forefront of IONIC's expansion and development into Washington state's leading vaporizer brand.

Andrew Schell, President, Vice-Chairman & Co-Founder, has built several successful companies. Schell has an engineering background rounded in operations, strategy and corporate law, and most recently was CEO of a U.S. Department of Defense company specializing in military operations.

Christian Struzan, Chief Marketing Officer & Co-Founder, has over 30 years of experience in marketing and branding in the entertainment and consumer goods industries. Struzan founded an advertising agency which developed and executed marketing campaigns for feature films such as the Star Wars franchise, Fight Club, and the television series American Idol. He has also worked on global brands such as Guinness, Stella Artois and Beck's.

Johnny Stange, Chief Revenue Officer, was formerly a director of sales for the southern California region for Treasury Wine Estates, a major wine wholesaler, where he grew and oversaw annual sales of $250 million. Stange is leading the charge in IONIC's aggressive sales growth plans across multiple states.

In 2018, IONIC was voted one of the "Top 50 Companies to Work for in Cannabis" by MG Magazine, a publication serving cannabis industry professionals.

IONIC Brands Corp. (OTC: ZRRRF), closed the day's trading session at $0.33, off by 2.94%, on 185,697 volume with 108 trades. The average volume for the last 3 months is 275,541 and the stock's 52-week low/high is $0.036/$0.635.

Recent News

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

During an era when geopolitical influences, automotive advances and market fluctuations have kept petroleum revenues well below historic record levels, pioneering technology developer Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is helping to revolutionize the oil and gas industry through the development of a cost-saving, environmentally friendly production platform.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil sands exploration and production on mineral leases in Vernal, Utah, and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 2,500-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Clean Oil Recovery Technology (CORT) System.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ. PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy Chairman Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

“API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy Inc. (PQEFF), closed the day's trading session at $0.27145, off by 9.41%, on 199,415 volume with 83 trades. The average volume for the last 3 months is 201,580 and the stock's 52-week low/high is $0.242/$1.43.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.